Status:
COMPLETED
Experimental Medication For the Treatment of Generalized Anxiety Disorder
Lead Sponsor:
Jazz Pharmaceuticals
Conditions:
Anxiety Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.
Detailed Description
Protocol 04-001-01 The primary objective of the study is to assess, under controlled conditions, the safety and efficacy of an experimental anti-anxiety medication relative to placebo in subjects wit...
Eligibility Criteria
Inclusion
- Subjects 18 to 65 years of age will be eligible to participate if they satisfy the DSM-IV-TR criteria for the diagnosis of GAD.
Exclusion
- No other primary psychiatric diagnosis besides GAD.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
511 Patients enrolled
Trial Details
Trial ID
NCT00097708
Start Date
November 1 2004
End Date
December 1 2005
Last Update
October 3 2014
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Research Group, Inc.
Birmingham, Alabama, United States, 35216
2
Crest Clinical Trials, Inc.
Anaheim, California, United States, 92804
3
Southwesten Research, Inc.
Beverly Hills, California, United States, 90210
4
Southwestern Research Institute
Burbank, California, United States, 91506